HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.

Abstract
It is well documented that cytotoxic treatment in patients carrying the hepatitis B virus (HBV) enhances the risk of severe hepatic damage. Recently lamivudine has been reported to be effective in suppressing the replication of HBV under such conditions. Here we report two cases with HBV carrier status and with non-Hodgkin's lymphoma who were successfully treated with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation with the administration of lamivudine to prevent HBV flare-up. The antiviral effect of lamivudine was fair, and no objective side effect was experienced during the transplant procedure. Both patients were followed carefully for more than a year without the appearance of the resistant virus. The rebound phenomenon in which HBV proliferates abruptly has not been experienced after withdrawal of lamivudine. We suggest that lamivudine is indicated both in the treatment of HBV viremia and in the prevention of proliferation of HBV in patients with HBV carrier status undergoing high-dose myeloablative chemotherapy.
AuthorsMasashi Nakagawa, Yoshifumi Simizu, Masaki Suemura, Bunzo Sato
JournalAmerican journal of hematology (Am J Hematol) Vol. 70 Issue 1 Pg. 60-3 (May 2002) ISSN: 0361-8609 [Print] United States
PMID11994984 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Reverse Transcriptase Inhibitors
  • Lamivudine
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Carrier State (virology)
  • Hematopoietic Stem Cell Transplantation
  • Hepatitis B (complications, drug therapy, virology)
  • Hepatitis B virus (drug effects, physiology)
  • Humans
  • Lamivudine (therapeutic use)
  • Lymphoma, Non-Hodgkin (complications, therapy)
  • Male
  • Middle Aged
  • Reverse Transcriptase Inhibitors (therapeutic use)
  • Secondary Prevention
  • Time Factors
  • Virus Activation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: